XORTX Historical Balance Sheet
XRTX Stock | USD 1.21 0.03 2.54% |
Trend analysis of XORTX Therapeutics balance sheet accounts such as Total Assets of 5 M, Other Current Liab of 83.2 K, Total Current Liabilities of 280.2 K or Total Stockholder Equity of 3.1 M provides information on XORTX Therapeutics' total assets, liabilities, and equity, which is the actual value of XORTX Therapeutics to its prevalent stockholders. By breaking down trends over time using XORTX Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining XORTX Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether XORTX Therapeutics is a good buy for the upcoming year.
XORTX Therapeutics Inventory |
|
XORTX |
About XORTX Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of XORTX Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. XORTX Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of XORTX Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which XORTX currently owns. An asset can also be divided into two categories, current and non-current.
XORTX Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of XORTX Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in XORTX Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on XORTX Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of XORTX Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Accounts Payable
An accounting item on the balance sheet that represents XORTX Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of XORTX Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most accounts from XORTX Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into XORTX Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.At this time, XORTX Therapeutics' Other Current Assets are fairly stable compared to the past year. Property Plant And Equipment Gross is likely to rise to about 144.8 K in 2024, whereas Total Assets are likely to drop slightly above 5 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 3.8M | 151.4K | 87.6K | 83.2K | Total Assets | 17.3M | 12.3M | 5.5M | 5.0M |
XORTX Therapeutics balance sheet Correlations
Click cells to compare fundamentals
XORTX Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
XORTX Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.1M | 2.3M | 17.3M | 12.3M | 5.5M | 5.0M | |
Other Current Liab | 641.5K | 728.4K | 3.8M | 151.4K | 87.6K | 83.2K | |
Total Current Liabilities | 1.3M | 1.0M | 4.2M | 1.5M | 294.9K | 280.2K | |
Total Stockholder Equity | (211.7K) | 1.3M | 13.1M | 7.0M | 4.6M | 3.1M | |
Property Plant And Equipment Net | 731.0 | 341.0 | 0.0 | 92.5K | 23.9K | 28.8K | |
Net Debt | (7.8K) | (171.3K) | (14.8M) | (10.3M) | (3.4M) | (3.6M) | |
Retained Earnings | (6.8M) | (8.0M) | (7.6M) | (14.1M) | (17.9M) | (17.0M) | |
Accounts Payable | 607.4K | 305.8K | 324.0K | 1.3M | 195.8K | 186.0K | |
Cash | 58.6K | 171.3K | 14.8M | 10.4M | 3.4M | 3.6M | |
Non Current Assets Total | 272.7K | 234.3K | 1.5M | 1.5M | 1.4M | 731.9K | |
Cash And Short Term Investments | 58.6K | 171.3K | 14.8M | 10.4M | 3.4M | 3.6M | |
Net Receivables | 15.5K | 14.4K | 40.7K | 81.8K | 60.7K | 35.1K | |
Common Stock Shares Outstanding | 595.5K | 740.4K | 1.1M | 1.5M | 2.0M | 2.1M | |
Liabilities And Stockholders Equity | 1.1M | 2.3M | 17.3M | 12.3M | 5.5M | 5.0M | |
Other Stockholder Equity | 683.0K | 0.0 | (1.4M) | (2.4M) | 5.5M | 5.8M | |
Total Liab | 1.3M | 1.0M | 4.2M | 5.4M | 825.9K | 784.6K | |
Total Current Assets | 815.2K | 2.1M | 15.8M | 10.9M | 4.1M | 4.2M | |
Short Long Term Debt Total | 272.5K | 43.3K | 50.8K | 77.4K | 11.5K | 10.9K | |
Intangible Assets | 272.4K | 234.3K | 201.0K | 199.4K | 175.3K | 189.0K | |
Net Tangible Assets | (484.1K) | 1.0M | 16.5M | 9.2M | 10.6M | 11.1M | |
Net Invested Capital | (160.9K) | 1.3M | 16.7M | 7.0M | 4.6M | 4.6M | |
Net Working Capital | (484.5K) | 1.0M | 14.9M | 9.4M | 3.8M | 4.3M | |
Other Current Assets | 741.2K | 2.1M | 1.0M | 379.6K | 560.4K | 728.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.